Stage M2/Ingénieur en Bioinformatique

 Stage · Stage M2  · 6 mois    Bac+5 / Master   Ciri - Virpath · Lyon 08 (France)

 Date de prise de poste : 2 janvier 2026

Mots-Clés

Omics integration AI Vaccines

Description

Context

The Virpath laboratory, co-directed by Dr. Manuel Rosa-Calatrava, focuses on respiratory viruses, developing translational research for drug repurposing and new vaccines. All computational work is managed by Nexomis, the lab’s bioinformatics core. The funded mRESPIVAC project aims to accelerate mRNA vaccine selection by generating and analyzing massive omics datasets to find predictors of vaccine effectiveness and safety. A key challenge is integrating underexploited public data, which these internships aim to address.

Offers

We have 3 positions for M2 students, with opportunities for a 1-year funded engineer position and a 3-year PhD studentship afterward. For more details on each position, please consult the links below.

Agentic AI-x-Bioinfo Workflow to Build a Fit-to-Purpose Database for Connectivity-Based Screening

This project focuses on building a specialized database for connectivity-based screening using a multi-agent AI system to automatically retrieve and structure data from public repositories.
(http://bit.ly/4lwUouG)

Workflow development for viral genomics & RNA-seq analysis

This internship aims to improve and expand existing Nextflow-based bioinformatics workflows for viral genomics and RNA-seq analysis, adding new features and ensuring code quality.
(https://bit.ly/4nXVi51)

Method Development for Multi-Omics Integration and Hub Gene Identification in Systems Immunology

This project’s objective is to develop a new computational method for integrating multi-omics data to identify key regulatory “hub genes” using a network-based approach.
(https://bit.ly/4lK7eGe)

Candidature

Procédure : Envoyer un mail à julien.fouret@univ-lyon1.fr

Date limite : 15 novembre 2025

Contacts

 Julien Fouret
 juNOSPAMlien.fouret@univ-lyon1.fr

Offre publiée le 21 juillet 2025, affichage jusqu'au 15 novembre 2025